Next Article in Journal
The Effect of a Mediterranean Diet on the Incidence of Cataract Surgery
Next Article in Special Issue
Impact of Maternal Selenium Status on Infant Outcome during the First 6 Months of Life
Previous Article in Journal
Dietary BCAA Intake Is Associated with Demographic, Socioeconomic and Lifestyle Factors in Residents of São Paulo, Brazil
Previous Article in Special Issue
Anti-Inflammatory Mechanism Involved in Pomegranate-Mediated Prevention of Breast Cancer: the Role of NF-κB and Nrf2 Signaling Pathways
Open AccessArticle

Neuroprotective Role of Atractylenolide-I in an In Vitro and In Vivo Model of Parkinson’s Disease

Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Korea
Author to whom correspondence should be addressed.
Nutrients 2017, 9(5), 451;
Received: 11 January 2017 / Revised: 24 February 2017 / Accepted: 20 March 2017 / Published: 2 May 2017
(This article belongs to the Special Issue Nutrients, Infectious and Inflammatory Diseases)
Parkinson’s disease (PD) is an age-related neurological disorder characterized by a loss of dopaminergic neurons within the midbrain. Neuroinflammation has been nominated as one of the key pathogenic features of PD. Recently, the inadequate pharmacotherapy and adverse effects of conventional drugs have spurred the development of unconventional medications in the treatment of PD. The purpose of this study is to investigate the anti-neuroinflammatory mechanisms of Atractylenolide-I (ATR-I) in in vivo and in vitro models of PD. Nitrite assay was measured via Griess reaction in lipopolysaccharide (LPS) stimulated BV-2 cells. mRNA and protein levels were determined by a reverse transcription-polymerase chain reaction (RT-PCR) and immunoblot analysis, respectively. Further, flow cytometry, immunocytochemistry, and immunohistochemistry were employed in BV-2 cells and MPTP-intoxicated C57BL6/J mice. Pre-treatment with ATR-I attenuated the inflammatory response in BV-2 cells by abating the nuclear translocation of nuclear factor-κB (NF-κB) and by inducing heme oxygenase-1 (HO-1). The intraperitoneal administration of ATR-I reversed MPTP-induced behavioral deficits, decreased microglial activation, and conferred protection to dopaminergic neurons in the mouse model of PD. Our experimental reports establish the involvement of multiple benevolent molecular events by ATR-I in MPTP-induced toxicity, which may aid in the development of ATR-I as a new therapeutic agent for the treatment of PD. View Full-Text
Keywords: Atractylenolide-I; astrocyte; microglia; neuroinflammation; Parkinson’s disease Atractylenolide-I; astrocyte; microglia; neuroinflammation; Parkinson’s disease
Show Figures

Figure 1

MDPI and ACS Style

More, S.; Choi, D.-K. Neuroprotective Role of Atractylenolide-I in an In Vitro and In Vivo Model of Parkinson’s Disease. Nutrients 2017, 9, 451.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop